Syneos Health inks deal with Microsoft to further use AI
MF3d         

Syneos Health (NASDAQ:SYNH) will leverage Microsoft's (NASDAQ:MSFT) Open AI platform to speed up clinical development and improve commercial performance for biopharma customers.
Syneos (SYNH) has already developed an advanced analytics platform that utilizes machine learning with Microsoft Azure.
The new multi-year agreement will allow Syneos (SYNH) to analyze data to fast-track timelines, optimize resource allocation, and unlock clinical trial efficiencies. The company said this will lead to better site selection and reduced enrollment timelines, potentially allowing new therapies to come to the market faster.
Read why Seeking Alpha contributor Zach Bristow considers Syneos (SYNH) a hold.